Overview of measles and mumps vaccine: Origin, present, and future of vaccine production

Acta Virologica

Volumn 57, Issue 2, 2013, Pages 91-96

  Betakova T ^a,b   Svetlikova D ^b   Gocnik M ^c  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b Centre for Molecular Medicine   (Slovakia)

^c IMUNA PHARM as   (Slovakia)

Author keywords

Cell substrates; Measles virus; Mumps virus; Vaccines

Indexed keywords

MEASLES VACCINE; MUMPS VACCINE;

ARTICLE; BLINDNESS; CHICK EMBRYO; CHO CELL; DIARRHEA; EAR INFECTION; ENCEPHALITIS; FIBROBLAST; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MEASLES; MEASLES VIRUS; MORTALITY; MUMPS; NONHUMAN; PATHOGENICITY; PNEUMONIA; VACCINATION; VACCINE PRODUCTION; VERO CELL;

ANIMALS; HUMANS; MEASLES; MEASLES VACCINE; MUMPS; MUMPS VACCINE; VIRAL VACCINES;

EID: 84880357986     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2013_02_91     Document Type: Article

References (35)

1. Afzal MA, Pickford AR, Forsey T, Minor PD,Lancet 340, 980-981, 1992. http://dx.doi.org/10.1016/0140-6736(92)92874-F
2. Afzal MA, Pickford AR, Yates PJ, Forsey T, Minor PD,J. Gen. Virol. 75, 1169-1172, 1994. http://dx.doi.org/10.1099/0022-1317-75-5-1169
3. Brown SW, Mehtali M,Pharm. Sci. Technol. 64, 419-425, 2010.
4. Buynak EB, Hilleman MR,Proc. Soc. Exp. Biol. Med. 123, 768-775, 1966.
5. Elango N, Varsanyi TM, Kövamees J,J. Gen. Virol. 69, 2893-2900, 1988. http://dx.doi.org/10.1099/0022-1317-69-11-2893
6. Elliott GD, Yeo RP, Afzal MA, Simpson EJ, Curran JA,Rima BK, J. Gen. Virol. 71, 1555-1560, 1990. http://dx.doi. org/10.1099/0022-1317-71-7-1555
7. Enders JF, Peebles TC,Proc. Soc. Exp. Biol. Med. 86, 277-286, 1954.
8. EMA/CHMP/BWP/68803/2010. Comitee for human medicinal products (CHPM) guideline on quality aspects on izolation of candidate influenza vaccine viruses in cell culture, draft; 14 April 2010, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guedeline/2010/06/WC500091535.pdf, http://tinyurl.com/6yj3c5j.
9. Grachev VP,Adv. Biotechnol. Processes 14, 37-67, 1990.
10. Griffin DE, Bellini WJ, In Fields BN, Knipe DM, Howley PM (Eds): Field's Virology. 3rd ed., Lippincott-Raven, New York,pp. 1267-1312, 1996.
11. Hayflick L, Plotkin S, Stevenson RE,Dev. Biol. Stand. 68, 9-17, 1987.
12. Hess RD, Weber F, Watson K, Schmitt S,Vaccine 30, 2715-2727, 2012. http://dx.doi.org/10.1016/j.vaccine.2012.02.015
13. Hviid A, Rubin S, Mühlemann K,Lancet 371, 932-944, 2008. http:// dx.doi.org/10.1016/S0140-6736(08)60419-5
14. Jacobs JP, Magrath DI, Garrett AJ, Schild GC,J. Biol. Stand. 9, 331-342, 1981. http://dx.doi.org/10.1016/S0092-1157(81)80058-3
15. Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V,Vaccine 27, 748-756, 2009. http://dx.doi.org/10.1016/j.vac-cine.2008.11.066
16. Levels & trends in child mortality report 2011: Estimates devel- oped by the UN Inter-agency Group for Child Mortality Estimation. New York, NY, United Nations Childrens Fund, 2011 (http://www.childinfo.org/files/Child_Mor-tality_Report_2011.pdf, accessed 11 March 2012).
17. Kubota T, Yokosawa N, Yokota S, Fujii N,Biochem. Biophys. Res. Commun. 283, 255-259, 2001. http://dx.doi.org/10.1006/bbrc.2001.4764
18. Kubota T, Yokosawa N, Yokota S, Fujii N, Tashiro M, Kato A,J. Virol. 79, 4451-4459, 2005. http://dx.doi.org/10.1128/JVI.79.7.4451-4459.2005
19. Lamb RA, Kolakofsky D, In Fields BN, Knipe DM, Howley PM (Eds): Field's Virology. 3rd ed., Lippincott-Raven, New York,pp. 1177-1204, 1996.
20. Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U,Vaccine 27, 4975-4982, 2009. http://dx.doi.org/10.1016/j.vac-cine.2009.05.083
21. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA,J. Virol. 75, 921-933, 2001a. http://dx.doi.org/10.1128/JVI.75.2.921-933.2001
22. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA,J. Virol. 75, 910-920, 2001b. http://dx.doi.org/10.1128/JVI.75.2.910-920.2001
23. Rota JS, Wang ZD, Rota PA, Bellini WJ,Virus Res. 31, 317-330, 1994. http://dx.doi.org/10.1016/0168-1702(94)90025-6
24. Schwarz AJ,Am J. Dis. Child. 103, 386-389, 1962.
25. Semba RD, Bloem MR,Surv Ophthalmol 49, 243-255, 2004. http://dx.doi.org/10.1016/j.survophthal.2003.12.005
26. The millennium development report 2009. New York, NY, United Nations, 2009 (http://mdgs.un.org/unsd/mdg/Resources/Static/Products/Progress2009/MDG_Report_2009_ En.pdf).01
27. Tillieux SL, Halsey WS, Sathe GM, Vassilev V,Vaccine 27, 2265-2273, 2009. http://dx.doi.org/10.1016/j.vaccine.2009.01.112
28. Ulane CM, Rodriguez JJ, Parisien JP, Horvath CM,J. Virol 77, 6385- 6393, 2003. http://dx.doi.org/10.1128/JVI.77.11.6385-6393.2003
29. Wilson RL, Fuentes SM, Wang P, Taddeo EC, Klatt A, Henderson AJ, He B,J. Virol. 80, 1700-1709, 2006. http://dx.doi. org/10.1128/JVI.80.4.1700-1709.2006
30. Wolfson LJ et al.,Int. J. Epidemiol. 38, 192-205, 2009. http://dx.doi. org/10.1093/ije/dyn224
31. WHO, WHO Technical Report Series, No. 878, 1998. www.who. int/entity/biologicals/publications/trs/areas/vaccines/ cells/WHO_TRS_878_A1Animalcells.pdf
32. WHO, Wkly Epidemiol. Rec. 79, 130-142, 2004.
33. WHO (2010), Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. http://www.who.int/biologicals/Cell_Substrates_clean_version_18_April.pdf
34. WHO (2012), Vaccine-preventable diseases: monitoring system 2012 global summary.http://apps.who.int/immuniza-tion_monitoring/en/globalsummary/timeseries/tsinci- dencemum.htm2007 2008
35. WHO (2012), Global measles and rubella strategic plan: 2012- 2020. ISBN 978 92 4 150339 6 (NLM classification: WC 500).